Companies › Applied Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Caficrestat (AT-001) Aldose reductase inhibitor | AKR1B1 | Phase 3 | Diabetic Cardiomyopathies | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04083339 | Caficrestat (AT-001) | Phase 3 | Diabetic Cardiomyopathies | Metabolic and endocrine | Dec 2023 |
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.